125 related articles for article (PubMed ID: 9490136)
21. [Molecular staging of hematogenous microdissemination of prostate cancer cells].
Kunimi K
Hinyokika Kiyo; 1996 Oct; 42(10):791-4. PubMed ID: 8951477
[TBL] [Abstract][Full Text] [Related]
22. Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells.
McIntyre IG; Spreckley K; Clarke RB; Anderson E; Clarke NW; George NJ
Br J Cancer; 2000 Oct; 83(8):992-7. PubMed ID: 10993644
[TBL] [Abstract][Full Text] [Related]
23. Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR.
Albers P; Ko Y; Wardelmann E; Schmidt D; Adam M; Vetter H; Müller SC
Anticancer Res; 2000; 20(3B):2107-11. PubMed ID: 10928161
[TBL] [Abstract][Full Text] [Related]
24. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
25. [Clinical surveillance after surgery for prostate cancer].
Guercio S; Terrone C; Scarpa RM
Recenti Prog Med; 2003 Mar; 94(3):110-3. PubMed ID: 12677777
[TBL] [Abstract][Full Text] [Related]
26. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
[TBL] [Abstract][Full Text] [Related]
27. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.
Ellis WJ; Vessella RL; Corey E; Arfman EW; Oswin MM; Melchior S; Lange PH
J Urol; 1998 Apr; 159(4):1134-8. PubMed ID: 9507816
[TBL] [Abstract][Full Text] [Related]
28. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
Ghossein RA; Rosai J
Cancer; 1996 Jul; 78(1):10-6. PubMed ID: 8646704
[TBL] [Abstract][Full Text] [Related]
29. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
30. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources.
Ravery V
Semin Urol Oncol; 1999 Aug; 17(3):127-9. PubMed ID: 10462314
[TBL] [Abstract][Full Text] [Related]
31. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
[TBL] [Abstract][Full Text] [Related]
32. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas.
Ghossein RA; Carusone L; Bhattacharya S
In Vivo; 2000; 14(1):237-50. PubMed ID: 10757082
[TBL] [Abstract][Full Text] [Related]
33. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
34. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Davis JW; Nakanishi H; Kumar VS; Bhadkamkar VA; McCormack R; Fritsche HA; Handy B; Gornet T; Babaian RJ
J Urol; 2008 Jun; 179(6):2187-91; discussion 2191. PubMed ID: 18423725
[TBL] [Abstract][Full Text] [Related]
36. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
[TBL] [Abstract][Full Text] [Related]
37. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
38. Estimation of total PSA with a supersensitive PSA-assay during neo-adjuvant-chemotherapy of prostate cancer before radical resection of prostate.
Spitz J; Enzmann T; Müller W; Weidenfeld M; Köllermann M
Anticancer Res; 1999; 19(4A):2637-40. PubMed ID: 10470209
[TBL] [Abstract][Full Text] [Related]
39. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
40. Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
Kurek R; Ylikoski A; Renneberg H; Konrad L; Aumüller G; Roddiger SJ; Zamboglou N; Tunn UW; Lilja H
Prostate; 2003 Sep; 56(4):263-9. PubMed ID: 12858354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
